All News

Given the vast technology problems many state-based exchanges experienced during the first open-enrollment period, state officials there and elsewhere remain wary of running their own websites.

Although the state and federal health insurance exchanges have most recently taken the national spotlight, attention may soon turn to private health exchanges.

The drug is to be administered right before chemotherapy or radiation, to bind to and inhibit cell division in normal cells and reduce the adverse effects of chemotherapy.

AstraZeneca has signed up Roche and Qiagen to develop two separate diagnostic tests, both using simple blood samples, to identify patients who will benefit from its lung cancer drugs.

The Obama administration and state insurance commissioners are developing new standards to oversee narrow networks as consumers begin to express concerns of limited physician choice and unexpected out-of-network costs.

New trial data confirms its use as standard therapy for CLL.

HIV-positive individuals are not usually enrolled in clinical trials, resulting in a knowledge-gap on their treatment options.

The chairmen of the House and Senate Veterans Affairs committees have reached a tentative agreement on a plan to improve veterans' healthcare.

The DNA testing firm hopes a more cooperative approach with regulators will get its business back on track.

U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.

This week, the nation turned its attention to the split rulings of 2 state federal court of appeals.

Active implementation of cost-saving measures successfully cut down expenditure at the Norris Comprehensive Cancer Center.

Uncompensated care was supposed to be a thing of the past, but it's persisting in many states not expanding Medicaid eligibility. As an alternative, for some high-cost uninsured patients, hospitals are turning to a new option.

When weighing the risk of heart disease, how the numbers are presented to patients can make all the difference.

Following the success of robotics in prostate surgeries, the technique was expected to provide comparable results for bladder cancer surgeries as well.

The University of Buffalo is working to limit patient readmissions to hospitals and ERs via use of dashboard technology.

Opdivo (Nivolumab) recently received regulatory approval in Japan for the treatment of patients with unresectable melanoma, the first global approval for a PD-1 inhibitor.

As healthcare reform advances, experts say, dermatologists face mounting pressure to prove their mettle to insurance exchanges and accountable care organizations (ACOs).

To better align the care of beneficiaries insured under both the Medicaid and Medicare programs, CMS invited states to participate in a 3-year demonstration project. However, it seems that many beneficiaries have opted out of these care coordination programs that are offered across the country.

A federal rule requiring health insurers to spend a minimum percentage of premium dollars on medical care led to more than $332 million in rebates last year, according to HHS.

The approval is a big gain for melanoma (Yervoy) and prostate cancer (Xtandi) patients in England and Wales.

However, a point to note is that this was a small cohort study without a comparator arm.

The drug has been approved for use in patient's with relapsed disease.

With diabetes costs taking double-digit increases--and expensive newer meds launching--insurers are tightening restrictions on drug use.

According to a recent survey, radiation oncologists are doing this for 7.9% less pay than they earned the year before.

Obamacare got taken for a roller-coaster ride on Tuesday when two different appeals courts took completely different takes on the latest challenges to the law.

A federal appeals court panel ruling in Washington, DC, if upheld, could majorly impact the Affordable Care Act.

HHS issued an interpretive rule that requires drug companies to provide discounts on orphan drugs sold through a federal program just months after a judge struck down the government's previous version of the rule.